Vera Therapeutics

Our Company

We are a clinical-stage biotechnology company focused on transforming patients’ lives by developing and commercializing treatments for immunological and inflammatory diseases.

Our lead clinical candidate, atacicept, is a novel inhibitor of B cells and plasma cells. We are developing atacicept, which is self-administered subcutaneously once per week, for the treatment of IgA nephropathy (IgAN), a rare autoimmune disease that can lead to dialysis or the need for a kidney transplant.

Currently, there are no approved treatments for IgAN. We are committed to changing that.

Our Values

Our values are the cornerstone of our culture. How we do things is just as important as what we achieve. Our values inspire us every day and guide everything we do—from the people we hire, to our mission, and to our ultimate goal to make a meaningful difference for patients suffering from immunological and inflammatory diseases.


Setting the highest standards and striving to achieve the most challenging goals are core to building a successful company. Being accountable to our stakeholders and purposefully moving forward no matter the obstacles allows us to build a great company and deliver on our promise to substantially improve standard of care for patients in need.


Developing new treatments for patients depends on highly effective teamwork. Each of our team members brings a unique skill set and a perspective that makes us able to bring effective medicines to patients suffering from devastating diseases. We are unified by our mission, and excel with organizational clarity and alignment.


Patients are the reason for Vera’s existence, and successful drug development depends on disciplined patient-focus. By having empathy for patients and understanding their needs, we create the opportunity to improve standard of care with our business. We constantly strive to earn and maintain the trust of the patients we serve.

Our Team

Marshall Fordyce

CEO and Founder

Lauren Frenz

Chief Business Officer

Joanne Curley

Chief Development Officer

Jonathan Wolter

Chief Financial Officer

Tom Doan

SVP Clinical Operations & Data Management

Board of Directors

Andrew Cheng

President and CEO, Akero Therapeutics

Beth Seidenberg

General Partner, Kleiner Perkins

Kurt von Emster

Managing Partner, Abingworth LLP

Maha Katabi

General Partner, Sofinnova Investments

Patrick Enright

Managing Director, Longitude Capital

Scott Morrison

Former Partner and US Life Sciences Leader, EY

Marshall Fordyce

President and CEO, Vera Therapeutics